Indicator strain | hSBA GMR (95% CI)† for follow-on cohort | hSBA GMR (95% CI)† for vaccine-naive cohort | |||
---|---|---|---|---|---|
Group 1 | Group 2 | Group 3 | Group 4 (dose 1) | Group 4 (dose 2) | |
H44/76 (fHbp response) | 99 (79–125) n = 95 | 67 (34–135) n = 10 | 133 (68–258) n = 11 | 10 (8.2–13) n = 175 | 105 (94–116) n = 175 |
5/99 (NadA response) | 70 (57–86) n = 92 | 51 (27–95) n = 10 | 55 (30–99) n = 11 | 29 (23–37) n = 168 | 299 (256–350) n = 172 |
NZ98/254 (PorA response) | 27 (21–36) n = 93 | 5.96 (2.7–13) n = 10 | 38 (18–81) n = 11 | 2.25 (1.84–2.75) n = 173 | 17 (14–19) n = 174 |
M10713 (NHBA response) | 5.24 (3.91–7.02) n = 88 | 7.06 (2.92–17) n = 9 | 7.35 (3.03–18) n = 9 | 2 (1.62– 2.46) n = 158 | 5.12 (3.95–6.65) n = 161 |
Note: CI = confidence interval, fHbp = factor H–binding protein, GMR = geometric mean ratio, hSBA = human serum bactericidal antibody, NadA = Neisserial adhesin A, PorA = porin A, NHBA = Neisseria heparin binding antigen. All participants in the follow-up cohort received 2 previous doses of 4CMenB vaccine at 12 and 14 mo (Group 1), 18 and 20 mo (Group 2) or 24 and 26 mo (Group 3) in a previous study.21 Group 4 included participants with no previous 4CMenB vaccination.
↵* Values of n are the no. of participants in the group with available results for that response.
↵† GMR is the ratio of geometric mean titre (GMT) postvaccination to prevaccination. Postvaccination GMT was measured 1 mo after each dose of vaccine, and prevaccination GMT was measured before any doses were given in this study. 95% CIs for GMRs were computed by taking the anti-log of mean values and the lower and upper limits of the 95% CIs.